Spatiotemporal complexity and druggability of PTH1R: insights from small molecules and peptides.
This review enhances understanding of PTH1R signaling, highlighting potential drug targets but requires further clinical validation.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpusSummary and findings
This review examines the spatiotemporal complexity and druggability of the parathyroid hormone type 1 receptor (PTH1R), focusing on small molecules and peptides. It highlights developments such as the Gs-biased agonist PCO371 and the non-peptidic allosteric modulator Pitt12. These findings contribute to understanding GPCR signaling and potential therapeutic applications.
Abstract
The parathyroid hormone type 1 receptor (PTH1R) is a class B GPCR that plays a vital role in calcium and phosphate homeostasis, bone turnover, and skeletal growth. It serves as a paradigmatic model for studying the spatial and temporal aspects of GPCR signaling, especially the prolonged cAMP signaling from endosomes and ligand-dependent location-biased agonism. Here, we review how small molecules and engineered peptides are advancing both the mechanistic understanding of this complex signaling process and its physiological significance, as well as drug discovery at PTH1R. Key developments include the orally administered small Gs-biased agonist PCO371, which binds the intracellular transmembrane region of the receptor; the negative non-peptidic allosteric modulator Pitt12, which decreases PTH-induced cAMP from an extracellular receptor vestibule; backbone-modified, conformationally selective peptides, which have dissected and advanced our understanding of the mechanism and biological relevance of endosomal cAMP signaling. Together, these tools are clarifying the structural basis of signaling bias and PTH1R's druggability, thereby enabling the development of therapies for bone and mineral diseases.
Background
The parathyroid hormone type 1 receptor (PTH1R) is crucial for calcium and phosphate homeostasis, bone turnover, and skeletal growth. Understanding its signaling pathways is essential for developing therapies for bone and mineral diseases. This study reviews recent advancements in small molecules and peptides that enhance the mechanistic understanding of PTH1R signaling.
Methods
This is a review article summarizing recent developments in the study of PTH1R, particularly focusing on small molecules and engineered peptides. It discusses various compounds, including Gs-biased agonists and allosteric modulators, and their roles in GPCR signaling.
Results
The review highlights several key developments, including the identification of PCO371, a Gs-biased agonist that binds the intracellular transmembrane region of PTH1R, and Pitt12, a negative allosteric modulator that affects cAMP signaling. It also discusses the role of backbone-modified peptides in elucidating endosomal cAMP signaling.
Interpretation
The findings provide insights into the structural basis of signaling bias and the druggability of PTH1R. While these developments are promising for drug discovery, the clinical significance of these findings needs further validation through human trials. The review contributes to the broader understanding of GPCR signaling but does not establish direct clinical applications.
Key findings
- PCO371 is an orally administered small Gs-biased agonist.
- Pitt12 is a negative non-peptidic allosteric modulator.
- Backbone-modified peptides aid in understanding endosomal cAMP signaling.
Limitations
- Review article, no new data
- Clinical relevance not established
- Focuses on mechanistic insights